Literature DB >> 12800450

[Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Rolf Ziesche1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12800450     DOI： 10.1007/bf03041488

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  51 in total

1.  Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation.

Authors:  B M Keck; L E Bennett; B S Fiol; O P Daily; R J Novick; J D Hosenpud
Journal:  Clin Transpl       Date:  1998

Review 2.  Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension.

Authors:  Norbert F Voelkel; Carlyne Cool; Laima Taraceviene-Stewart; Mark W Geraci; Michael Yeager; Todd Bull; Michael Kasper; Rubin M Tuder
Journal:  Crit Care Med       Date:  2002-05       Impact factor: 7.598

3.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

4.  Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.

Authors:  Syed H E Zaidi; Xiao-Mang You; Sorana Ciura; Mansoor Husain; Marlene Rabinovitch
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

5.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

6.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Authors:  O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

7.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

Authors:  J Sandoval; J Gaspar; T Pulido; E Bautista; M L Martínez-Guerra; M Zeballos; A Palomar; A Gómez
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

8.  The place of prostacyclin in the clinical management of primary pulmonary hypertension.

Authors:  T Higenbottam
Journal:  Am Rev Respir Dis       Date:  1987-09

9.  Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

Authors:  T Higenbottam; A Y Butt; A McMahon; R Westerbeck; L Sharples
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245
View more
  2 in total

1.  Oxidative stress in patients with COPD and pulmonary hypertension.

Authors:  Pavol Joppa; Darina Petrásová; Branislav Stancák; Zuzana Dorková; Ruzena Tkácová
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD.

Authors:  Karin Vonbank; Georg Christian Funk; Beatrice Marzluf; Bernhard Burian; Rolf Ziesche; Leopold Stiebellehner; Ventzislav Petkov; Paul Haber
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.